EXTON, Pa., Oct. 27 /PRNewswire-FirstCall/ -- ViroPharma Incorporated was recently named to the Deloitte 2006 Greater Philadelphia Technology Fast 50 Companies list as well as being ranked 63rd fastest growing company in North America on Deloitte's Fast 500, a ranking of the fastest growing technology, media, telecommunications and life sciences companies in North America. Rankings are based on percentage revenue growth over five years, from 2001-2005. ViroPharma grew 3,812 percent during this period. ViroPharma was also named top life sciences company for 2006 in the Greater Philadelphia Region.
"This is truly a great achievement and honor," commented Michel de Rosen, ViroPharma's chief executive officer. "The Philadelphia region is full of leading technology and life sciences companies. To be named to Deloitte's Fast 500 Companies for North America and the Fast 50 for the Greater Philadelphia region is a testament to each and every member of the ViroPharma family's unwavering commitment to our end goal - saving lives."
"Deloitte's Greater Philadelphia Technology Fast 50 companies have shown the strength, vision, and tenacity to succeed in today's very competitive technology environment," said R. Terry Hisey, National Sector Leader for Life Sciences, Deloitte Consulting LLP. "We applaud the successes of ViroPharma and acknowledge it as one of the very few to accomplish such a fast growth rate over the past five years."
"Making Deloitte's Technology Fast 500 is commendable in today's highly competitive technology industry," added Tony Kern, deputy managing principal of Deloitte's Technology, Media & Telecommunications industry practice.
The Greater Philadelphia Technology Fast 50 was created to recognize businesses in the Eastern Pennsylvania and Delaware region. Awards were determined based on percentages of revenue growth for five years in the areas of media, telecommunications, technology, and life sciences. Awards for the 2006 Fast 50 were presented October 25, 2006, at the World Cafe Live.
About ViroPharma Incorporated
ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin- resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/pulvules_pi.pdf). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.
About Deloitte
Deloitte refers to one or more of Deloitte Touche Tohmatsu, a Swiss Verein, its member firms, and their respective subsidiaries and affiliates. Deloitte Touche Tohmatsu is an organization of member firms around the world devoted to excellence in providing professional services and advice, focused on client service through a global strategy executed locally in nearly 150 countries. With access to the deep intellectual capital of approximately 135,000 people worldwide, Deloitte delivers services in four professional areas-audit, tax, consulting and financial advisory services - and serves more than one-half of the world's largest companies, as well as large national enterprises, public institutions, locally important clients, and successful, fast-growing global growth companies. Services are not provided by the Deloitte Touche Tohmatsu Verein, and, for regulatory and other reasons, certain member firms do not provide services in all four professional areas. As a Swiss Verein (association), neither Deloitte Touche Tohmatsu nor any of its member firms has any liability for each other's acts or omissions. Each of the member firms is a separate and independent legal entity operating under the names "Deloitte," "Deloitte & Touche," "Deloitte Touche Tohmatsu," or other related names.
In the United States, Deloitte & Touche USA LLP is the member firm of Deloitte Touche Tohmatsu, and services are provided by the subsidiaries of Deloitte & Touche USA LLP (Deloitte & Touche LLP, Deloitte Consulting LLP, Deloitte Financial Advisory Services LLP, Deloitte Tax LLP, and their subsidiaries), and not by Deloitte & Touche USA LLP. The subsidiaries of the U.S. member firm are among the nation's leading professional services firms, providing audit, tax, consulting, and financial advisory services through nearly 40,000 people in more than 90 cities. Known as an employer of choice for innovative human resources programs, it is dedicated to helping their clients and their people excel. For more information, please visit the U.S. member firm's Web site at http://www.deloitte.com/us.
ViroPharma IncorporatedCONTACT: William C. Roberts, Director, Corporate Communications,+1-610-321-6288, or Robert A. Doody, Manager, Corporate Communications,+1-610-321-6290, both of ViroPharma Incorporated
